Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 5,151 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 5,151 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $50.00, for a total value of $257,550.00. Following the completion of the sale, the director now owns 300,695 shares in the company, valued at $15,034,750. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pro-Dex Price Performance

Shares of PDEX opened at $48.89 on Tuesday. Pro-Dex, Inc. has a 52-week low of $16.84 and a 52-week high of $59.60. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58. The business’s 50 day moving average price is $39.79 and its two-hundred day moving average price is $38.48. The firm has a market cap of $159.43 million, a PE ratio of 24.32 and a beta of 0.68.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. On average, equities analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current year.

Hedge Funds Weigh In On Pro-Dex

Several institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp lifted its stake in Pro-Dex by 14.1% in the fourth quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier’s stock valued at $1,672,000 after buying an additional 4,426 shares during the period. Geode Capital Management LLC raised its position in shares of Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after purchasing an additional 2,296 shares during the period. JPMorgan Chase & Co. raised its position in shares of Pro-Dex by 2.2% during the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after purchasing an additional 529 shares during the period. EAM Investors LLC acquired a new position in shares of Pro-Dex during the fourth quarter worth approximately $1,047,000. Finally, O Shaughnessy Asset Management LLC acquired a new position in shares of Pro-Dex during the fourth quarter worth approximately $995,000. 15.28% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com lowered Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.